In the STEP 1 semaglutide trial (Wilding et al., NEJM , 2021) and the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM , 2022), nausea affected roughly 44% of semaglutide patients and about 24% of tirzepatide patients at the maximum dose
In general, Mounjaro tends to have more consistent coverage for type 2 diabetes, while Zepbound may be covered for OSA
Over a median follow-up of 4 years, the results told a clear story
Most side effects are temporary and manageable with proper titration and dietary adjustments
Novo Nordisk makes Ozempic, a product that underwent the FDAs approval process
PAP also excludes Medicare beneficiaries, and you should verify the current rules at novocare.com/diabetes/help-with-costs/pap.html before relying on it